Company Profile

  • Company Name
    aiwell Inc.
  • Establishment
    January 23, 2018
  • Representative
  • Location
    • Head Office
    • 〒102-0084
      9-3 Nibancho, Chiyoda-ku, Tokyo
    • Campus Innovation Center Tamachi
    • 〒108-0023
      3-3-6 Shibaura, Minato-ku, Tokyo
      Campus Innovation Center Tokyo 507
    • Tokyo Institute of Technology
      aiwell AI Proteomics Collaborative Research Center
    • 〒152-8550
      2-12-1 Ookayama, Meguro-ku, Tokyo
      M6-11 Midorigaoka Building 6 402A
    • Kobe Lab
    • 〒650-0047
      6-3-7 Minatojima Minamimachi, Chuo-ku, Kobe
      Creative Lab Kobe
    • aiwell Nordic ApS
    • Ole Maaløes Vej 3 DK-2200 København N
  • Capital
    323,859,000 yen (as of Dec 2022)
  • Main Shareholder
    Representative, Yokogawa Electric Corporation, Burroughs Inc, DIGIMERCE Inc, Taisho Pharmaceutical Co., Ltd., Future Food Fund Inc., and individual investors
  • Business description
    • Realization of mass image data intercomparison by digital imaging and analysis of proteins from human, animals and other living organisms from trace amounts of samples in collaboration with Tokyo Institute of Technology.
    • Providing services to support drug discovery, diagnosis and remote medical care using AI before worsening of symptoms or onset of subjective symptoms under the mission 「Eliminating illnesses from the world and keep people healthy」
  • Suppliers
    Tokyo Institute of Technology, Sapporo Medical University, Consadole Co., Ltd., R-body project, Kirin Holdings Co., Ltd., Yokogawa Electric Corporation. Sumitomo Dainippon Pharma Co., Ltd. Taisho Pharmaceutical Co., Ltd.